This forthcoming change to a 2-dose schedule follows on from advice from the Joint Committee on Vaccination and Immunisation (JCVI).
Recent research shows that antibody response to the 2 dose schedule in adolescent girls is equivalent to the response that correlated with protection against persistent infection and precancerous lesions in the initial vaccine trials. Both Gardasil® and Cervarix® have been approved for use in a 2 dose schedule.
An updated Q & A for health professionals and revised information leaflet will be available from mid-June.